Skip to main content
Premium Trial:

Request an Annual Quote

SeqWright Makes Second Investment in VisiGen; ABI Expected to Start Alliance Before End of Year

NEW YORK, Nov. 2 (GenomeWeb News) - SeqWright has made a much-anticipated and undisclosed follow-on investment in Visigen Biotechnologies, meeting a key condition that would have kept Applied Biosystems from making its own investment in the next-generation sequencing company, SeqWright and VisiGen said today.

 

As GenomeWeb News reported a year ago, SeqWright paid an undisclosed amount of cash for VisiGen stock to become a shareholder. The new investment helps clear the way for ABI to invest in and collaborate with VisiGen. The companies expect that VisiGen's collaboration with ABI will begin by the end of the calendar year.

 

VisiGen, based in Houston, is developing a real-time sequencing system to reduce the cost of DNA sequencing.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.